Loading...
Loading...
INAB| Name | Value |
|---|---|
| Revenues | 3,748.0K |
| Cost of Revenue | 627.0K |
| Gross Profit | 3,121.0K |
| Operating Expense | 6,971.0K |
| Operating I/L | -7,598.0K |
| Other Income/Expense | 330.0K |
| Interest Income | 0.0K |
| Pretax | -7,598.0K |
| Income Tax Expense | -7,598.0K |
| Net Income/Loss | -7,598.0K |
IN8bio, Inc. is a clinical-stage biotechnology company specializing in the development and commercialization of gamma-delta T cell therapies for cancer treatment. Its lead product, INB-200, is a genetically modified autologous gamma-delta T cell product candidate in Phase I clinical trial for glioblastoma and solid tumors. Additionally, the company is developing INB-100, an allogeneic product candidate in Phase I clinical trial for acute leukemia patients undergoing hematopoietic stem cell transplantation, as well as preclinical phase products, INB-400 and INB-300, for various solid tumor cancers.
